Clinical Trials
47 trialsMK-5684-01A
Merck Sharp & Dohme LLC
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
IDeate-Prostate02
Merck Sharp & Dohme LLC
QUEST
Janssen Research & Development, LLC
KLK2-PASenger
Janssen Research & Development, LLC
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
MAGNITUDE
Janssen Research & Development, LLC
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
SECuRE
Clarity Pharmaceuticals Ltd
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
AMX-500
Vir Biotechnology, Inc.
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Celcuity Inc
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
T.O.A.D. Oncology SA
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Tamarack
MacroGenics
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
ENGAGER-PSMA-01
Janux Therapeutics
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Bayer
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lantheus Medical Imaging
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
IMbassador250
Hoffmann-La Roche
VERACITY
Veru Inc.
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hoffmann-La Roche
Safety and Targeting of Anti-hk2 Antibody in mCRPC
SpectronRX
DaroAcT
Bayer
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
Nuvation Bio Inc.
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
PARABO
Bayer
URANIS
Bayer
TasQ003
Ipsen
BELFIGO
Bayer
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K.
Navigant
Bayer
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC